000290620 001__ 290620
000290620 005__ 20241105142652.0
000290620 0247_ $$2doi$$a10.1093/neuonc/noae092
000290620 0247_ $$2pmid$$apmid:38835160
000290620 0247_ $$2ISSN$$a1522-8517
000290620 0247_ $$2ISSN$$a1523-5866
000290620 0247_ $$2altmetric$$aaltmetric:164222919
000290620 037__ $$aDKFZ-2024-01206
000290620 041__ $$aEnglish
000290620 082__ $$a610
000290620 1001_ $$00000-0003-3302-2719$$aMynarek, Martin$$b0
000290620 245__ $$aRisk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa - Results of the HIT 2000 trial.
000290620 260__ $$aOxford$$bOxford Univ. Press$$c2024
000290620 3367_ $$2DRIVER$$aarticle
000290620 3367_ $$2DataCite$$aOutput Types/Journal article
000290620 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730813180_11577
000290620 3367_ $$2BibTeX$$aARTICLE
000290620 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290620 3367_ $$00$$2EndNote$$aJournal Article
000290620 500__ $$a2024 Nov 4;26(11):2113-2124
000290620 520__ $$aNeurocognition can be severely affected in pediatric brain tumor survivors. We analyzed the association of cognitive functioning with radiotherapy dose, postoperative cerebellar mutism syndrome (pCMS), hydrocephalus, intraventricular methotrexate (MTX) application, tumor localization and biology in pediatric survivors of a posterior fossa tumor.Subdomain-specific neurocognitive outcome data from 279 relapse-free survivors of the HIT-2000 trial (241 medulloblastoma and 38 infratentorial ependymoma) using the Neuropsychological Basic Diagnostic (NBD) tool based on Cattell-Horn-Carroll's model for intelligence were analyzed.Cognitive performance 5.14 years (mean; range=1.52-13.02) after diagnosis was significantly below normal for all subtests. Processing speed and psychomotor abilities were most affected. Influencing factors were domain-specific: CSI-dose had strong impact on most subtests. pCMS was associated with psychomotor abilities (β=-0.25 to -0.16) and processing speed (β=-0.32). Postoperative hydrocephalus correlated with crystallized intelligence (β=-0.20) and short-term memory (β=-0.15), age with crystallized intelligence (β=0.15) and psychomotor abilities (β=-0.16 and β=-0.17). Scores for fluid intelligence (β=-0.23), short-term memory (β=-0.17) and visual processing (β=-0.25) declined, and scores for selective attention improved (β=0.29) with time after diagnosis.Dose of CSI was strongly associated with neurocognitive outcome. Low psychomotor abilities and processing speed both in patients treated with and without CSI suggest a strong contribution of the tumor and its surgery on these functions. Future research therefore should analyze strategies to both reduce CSI-dose and toxicity caused by other treatment modalities.
000290620 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000290620 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290620 650_7 $$2Other$$aInfant
000290620 650_7 $$2Other$$aependymoma
000290620 650_7 $$2Other$$amedulloblastoma
000290620 650_7 $$2Other$$aneuropsychological late effects
000290620 650_7 $$2Other$$aquality of survival
000290620 7001_ $$aRossius, Anne$$b1
000290620 7001_ $$aGuiard, Anika$$b2
000290620 7001_ $$aOttensmeier, Holger$$b3
000290620 7001_ $$avon Hoff, Katja$$b4
000290620 7001_ $$aObrecht-Sturm, Denise$$b5
000290620 7001_ $$00000-0003-3888-1360$$aBußenius, Lisa$$b6
000290620 7001_ $$aFriedrich, Carsten$$b7
000290620 7001_ $$avon Bueren, Andre O$$b8
000290620 7001_ $$aGerber, Nicolas U$$b9
000290620 7001_ $$aTraunwieser, Thomas$$b10
000290620 7001_ $$00000-0002-8952-1819$$aKortmann, Rolf-Dieter$$b11
000290620 7001_ $$00000-0002-3544-319X$$aWarmuth-Metz, Monika$$b12
000290620 7001_ $$aBison, Brigitte$$b13
000290620 7001_ $$aThomale, Ulrich-W$$b14
000290620 7001_ $$aKrauss, Juergen$$b15
000290620 7001_ $$00000-0003-0763-6506$$aPietsch, Torsten$$b16
000290620 7001_ $$aClifford, Steven C$$b17
000290620 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b18$$udkfz
000290620 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b19$$udkfz
000290620 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b20$$udkfz
000290620 7001_ $$aTischler, Tanja$$b21
000290620 7001_ $$aRutkowski, Stefan$$b22
000290620 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae092$$gp. noae092$$n11$$p2113-2124$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
000290620 909CO $$ooai:inrepo02.dkfz.de:290620$$pVDB
000290620 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000290620 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000290620 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000290620 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000290620 9141_ $$y2024
000290620 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000290620 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000290620 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000290620 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000290620 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000290620 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000290620 980__ $$ajournal
000290620 980__ $$aVDB
000290620 980__ $$aI:(DE-He78)B062-20160331
000290620 980__ $$aI:(DE-He78)HD01-20160331
000290620 980__ $$aI:(DE-He78)B300-20160331
000290620 980__ $$aUNRESTRICTED